Amgen: Arthritis, Psoriatic trials

The registry lists 22 Arthritis, Psoriatic studies with Amgen as lead sponsor. 0 are open to participants now and 14 have results posted.

Phase 2 2Phase 3 10Phase 4 4No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic ArthritisCompletedNCT03783026Phase 4Results posted
• Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.CompletedNCT03747939Phase 4Results posted
• Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic ArthritisCompletedNCT02986139Phase 3Results posted
• Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic ArthritisCompletedNCT02376790Phase 3Results posted
• Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type PsoriasisCompletedNCT01988103Phase 2Results posted
• Safety and Efficacy Study of Apremilast to Treat Psoriatic ArthritisCompletedNCT01925768Phase 3Results posted
• Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject EtanerceptCompletedNCT01901185Phase 3Results posted
• Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque PsoriasisCompletedNCT01690299Phase 3Results posted
• Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)CompletedNCT01307423Phase 3Results posted
• PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic ArthritisCompletedNCT01212770Phase 3Results posted
• PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic ArthritisCompletedNCT01212757Phase 3Results posted
• Efficacy and Safety Study of Apremilast to Treat Active Psoriatic ArthritisCompletedNCT01172938Phase 3Results posted
• Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic ArthritisCompletedNCT00456092Phase 2Results posted
• REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)CompletedNCT00127842Phase 4Results posted
• A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological TreatmentCompletedNCT03828045
• Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)CompletedNCT03608657
• Post-Marketing Surveillance Study of OTEZLACompletedNCT03284879
• Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice ConditionsCompletedNCT03106051
• A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in BelgiumCompletedNCT03096990
• A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The NetherlandsCompletedNCT02875184
• Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and PsoriasisCompletedNCT00317499Phase 3
• Enbrel® in Psoriatic ArthritisCompletedNCT00111124Phase 4